%0 Journal Article
%A X., Long
%A L., Qi
%A X., Zu
%A Y., Li
%A W., He
%A S., Pi
%A X., Chen
%A K., Zhou
%A X., Hu
%A M., Chen
%D 2016
%T Supplementary Material for: Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed
%U https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Prevention_of_Recurrent_Bladder_Tumors_after_Nephroureterectomy_for_Primary_Upper_Urinary_Tract_Urothelial_Carcinoma_An_Individualized_Selection_Strategy_Based_on_Patient_Risk_Stratification_Is_Needed/4233158
%R 10.6084/m9.figshare.4233158.v2
%2 https://karger.figshare.com/ndownloader/files/6903746
%K Intravesical chemotherapy
%K Neoplasm recurrence
%K Urothelium
%K Urinary bladder
%K Urinary tract
%X Objective: To evaluate the efficacies of different chemotherapy regimens in different risk sub-groups for the prevention of bladder recurrence after radical nephroureterectomy (RNU). Materials and Methods: Between 2004 and 2012, we recruited 685 patients who underwent RNU for upper tract urothelial carcinoma at 4 Chinese institutions. We assessed whether the type of intravesical chemotherapy regimen affected the bladder recurrence rate in patients with different risk levels after RNU. Results: For all patients, the bladder recurrence rate was lower with intravesical chemotherapy than without, but no significant differences were found between the 2 intravesical chemotherapy regimens (single dose or relatively long-term therapy). We used multivariate analysis to define the risk factors for bladder recurrence and stratified patients into low-, intermediate-, and high-risk sub-groups accordingly. The bladder recurrence rate in the low-risk patients was not significantly different between patients with or without intravesical chemotherapy. However, in the intermediate-risk and high-risk patients, the rate was greater in patients without intravesical chemotherapy than in patients with. Furthermore, the rate was not significantly different between the 2 intravesical chemotherapy regimens in the intermediate-risk patients, while the efficacy of the relatively long-term regimen in high-risk patients remains unclear. Conclusions: Our study showed that an individualized strategy based on patient risk stratification is needed.
%I Karger Publishers